| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
61,398,000 |
| Market
Cap: |
283.66(M) |
| Last
Volume: |
821,939 |
Avg
Vol: |
693,736 |
| 52
Week Range: |
$3.38 - $6.95 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 803 |
| Guru Rank Value : 1 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vanda Pharmaceuticals is a biopharmaceutical company. Co.'s commercial portfolio is comprised of two products, HETLIOZ® for the treatment of Non-24 Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome and Fanapt® for the treatment of schizophrenia. In addition, Co. has a number of drugs in development, including: Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia; and VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
121,098 |
121,098 |
148,134 |
388,157 |
| Total Sell Value |
$513,345 |
$513,345 |
$684,141 |
$2,735,436 |
| Total People Sold |
5 |
5 |
6 |
8 |
| Total Sell Transactions |
10 |
10 |
14 |
33 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2019-03-04 |
4 |
S |
$19.41 |
$740,802 |
D/D |
(38,166) |
1,178,970 |
|
- |
|
| Reverberi Gian Piero |
SVP & Chief Commercial Officer |
• – – |
2019-03-01 |
4 |
S |
$20.17 |
$8,832 |
D/D |
(438) |
168,432 |
|
- |
|
| Birznieks Gunther |
SVP, Business Development |
• – – |
2019-03-01 |
4 |
S |
$20.14 |
$75,325 |
D/D |
(3,741) |
160,039 |
|
- |
|
| Kelly James Patrick |
EVP & Chief Financial Officer |
• – – |
2019-03-01 |
4 |
S |
$20.15 |
$100,271 |
D/D |
(4,976) |
218,497 |
|
- |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2019-03-01 |
4 |
S |
$20.22 |
$131,424 |
D/D |
(6,500) |
1,217,136 |
|
- |
|
| Williams Timothy |
SVP & General Counsel |
• – – |
2019-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
60,000 |
|
- |
|
| Kelly James Patrick |
EVP & Chief Financial Officer |
• – – |
2019-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
223,473 |
|
- |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2019-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
1,223,636 |
|
- |
|
| Reverberi Gian Piero |
SVP & Chief Commercial Officer |
• – – |
2019-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
168,870 |
|
- |
|
| Birznieks Gunther |
SVP, Business Development |
• – – |
2019-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
163,780 |
|
- |
|
| Kelly James Patrick |
EVP & Chief Financial Officer |
• – – |
2019-01-03 |
4 |
S |
$26.09 |
$42,232 |
D/D |
(1,619) |
193,473 |
|
- |
|
| Birznieks Gunther |
SVP, Business Development |
• – – |
2019-01-03 |
4 |
S |
$26.09 |
$42,232 |
D/D |
(1,619) |
133,780 |
|
- |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2019-01-03 |
4 |
S |
$26.04 |
$115,804 |
D/D |
(4,447) |
1,163,636 |
|
- |
|
| Reverberi Gian Piero |
SVP & Chief Commercial Officer |
• – – |
2019-01-02 |
4 |
S |
$26.28 |
$30,042 |
D/D |
(1,130) |
138,870 |
|
- |
|
| Kelly James Patrick |
EVP & Chief Financial Officer |
• – – |
2019-01-02 |
4 |
S |
$26.31 |
$117,579 |
D/D |
(4,442) |
195,092 |
|
- |
|
| Birznieks Gunther |
SVP, Business Development |
• – – |
2019-01-02 |
4 |
S |
$26.30 |
$117,578 |
D/D |
(4,442) |
135,399 |
|
- |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2019-01-02 |
4 |
S |
$26.32 |
$285,858 |
D/D |
(10,789) |
1,168,083 |
|
- |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2018-12-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,000 |
1,178,872 |
|
- |
|
| Williams Timothy |
SVP & General Counsel |
• – – |
2018-08-13 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Cola Michael F |
Director |
– • – |
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
10,000 |
|
- |
|
| Watkins Thomas |
Director |
– • – |
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
25,000 |
|
- |
|
| Milano Vincent |
Director |
– • – |
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
10,000 |
|
- |
|
| Dugan Richard W |
Director |
– • – |
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
30,770 |
|
- |
|
| Watkins Thomas |
Director |
– • – |
2018-05-03 |
4 |
OE |
$4.98 |
$74,700 |
D/D |
15,000 |
20,000 |
|
- |
|
| Dugan Richard W |
Director |
– • – |
2018-03-19 |
4 |
OE |
$4.98 |
$74,700 |
D/D |
15,000 |
25,770 |
|
- |
|
549 Records found
|
|
Page 8 of 22 |
|
|
0.14 (3.12%) 
